Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Acquires Shares of 659,076 Mineralys Therapeutics, Inc. $MLYS

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 659,076 shares of the company’s stock, valued at approximately $23,918,000. Mineralys Therapeutics comprises about 2.1% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s investment portfolio, making the stock its 18th largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.83% of Mineralys Therapeutics as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Navalign LLC purchased a new stake in shares of Mineralys Therapeutics in the 4th quarter valued at approximately $33,000. Smartleaf Asset Management LLC increased its position in shares of Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Mineralys Therapeutics by 14,091.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after purchasing an additional 3,241 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mineralys Therapeutics by 50.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,846 shares of the company’s stock valued at $140,000 after purchasing an additional 1,283 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of Mineralys Therapeutics in the 3rd quarter valued at approximately $216,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Mineralys Therapeutics news, Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the sale, the director directly owned 6,200 shares of the company’s stock, valued at $155,000. This represents a 32.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. acquired 310,700 shares of the firm’s stock in a transaction on Friday, March 27th. The shares were bought at an average cost of $23.67 per share, with a total value of $7,354,269.00. Following the completion of the transaction, the director directly owned 5,767,221 shares in the company, valued at $136,510,121.07. This trade represents a 5.69% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have sold 153,772 shares of company stock worth $4,121,668. Insiders own 18.94% of the company’s stock.

Wall Street Analyst Weigh In

MLYS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen began coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Mineralys Therapeutics Price Performance

NASDAQ MLYS opened at $23.76 on Thursday. The firm’s fifty day moving average price is $27.94 and its 200 day moving average price is $30.78. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -11.59 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.04. As a group, sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.